Remarkable prolonged progression-free survival time after therapy with trifluridine/ tipiracil. A case report of 57-year-old woman with metastatic colorectal cancer Case report

Article Sidebar

PDF


Published: Mar 31, 2020
DOI: https://doi.org/10.24292/01.OR.120250320
Keywords:
colorectal cancer, chemotherapy, trifluridine/tipiracil

Main Article Content

Marlena Orlikowska
Oncology and Chemotherapy Outpatient Clinic, Hospital in Starogard Gdański

Abstract

Colorectal cancer is the second leading cause of cancer-related death worldwide. Trifluridine/tipiracil is a novel orally administered antineoplasmatic thymidine-based nucleoside analog which represents an approved option for the treatment of advanced metastatic colorectal cancer in patients who are refractory, or are not considered candidates for, currently available therapies. In this report, we present a case of chemotherapy using trifluridine/tipiracil confirming the effectiveness of this drug primarily in the term of prolongation of progression free survival

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Orlikowska M. Remarkable prolonged progression-free survival time after therapy with trifluridine/ tipiracil. A case report of 57-year-old woman with metastatic colorectal cancer. OncoReview [Internet]. 2020Mar.31 [cited 2024May11];10(1(37):27-0. Available from: https://www.journalsmededu.pl/index.php/OncoReview/article/view/1080
Issue
Vol 10 No 1(37) (2020)
Section
CARDIO-ONCOLOGY
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. International Agency for Research on Cancer: GLOBOCAN 2018. http://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf .
2. Center MM, Jemal A, Smith RA et al. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009; 59: 366-78.
3. Wilkes GM. Metastatic colorectal cancer: management challenges and opportunities. Oncology. 2011; 25(7): 32-44.
4. Lenz HJ, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treatment Rev. 2015; 41: 777-83.
5. Burness CB, Duggan ST. Trifluridine/tipiracil: a review in metastatic colorectal cancer. Drugs. 2016; 76: 1393-402.
6. Mayer R, Van Cutsem E, Falcone A et al. RECOURSE Study Group Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015; 372: 1909-19.
7. Van Cutsem E, Cervantes A, Adam R et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27 (8): 1386-422.
8. European Medicines Agency. European public assessment report (EPAR) for Lonsurf. 2016. http://www.ema.europa.eu.